☆ 4.7 Editorial Material

Improving Prostate-Specific Antigen Screening

JOURNAL OF CLINICAL ONCOLOGY (2010)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 28, 期 15, 页码 2491-2492

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2009.26.9779

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Chemistry, Analytical

Screening of peptide selectively recognizing prostate-specific antigen and its application in detecting total prostate-specific antigen

Yanbo Wang, Mingyang Wang, Haipeng Yu, Ge Wang, Pengxin Ma, Shuang Pang, Yiming Jiao, Aihua Liu

Summary: PSA is an important index for prostate cancer diagnosis and treatment. In this study, a biopanning method for PSA was established using a pIII phage display library. Two phage monoclonal antibodies specific to PSA were obtained, and an ELISA system was constructed for detecting tPSA with high accuracy.

SENSORS AND ACTUATORS B-CHEMICAL (2022)

添加到收藏夹

Review Andrology

Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options

Tushar Aditya Narain, Prasanna Sooriakumaran

Summary: PSA is a well-known biomarker used for screening, diagnosis, and follow-up of prostate cancer patients. Due to its limitations, newer blood and urinary biomarkers have been evaluated to improve detection and risk stratification. A combination of these markers, clinical risk factors, and advances in imaging offer the potential for better diagnostic performance and clearer risk stratification to guide therapeutics.

WORLD JOURNAL OF MENS HEALTH (2022)

添加到收藏夹

Article Urology & Nephrology

Prostate Specific Antigen and Biopsy Contamination in the Goteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial

K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman

Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.

JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Screening for Prostate Cancer

Paul F. Pinsky, Howard Parnes

Summary: Screening for prostate cancer should take into consideration the risks and benefits. PSA screening can reduce prostate cancer deaths, but the reduction is small. Follow-up tests such as biopsy and MRI may be needed for individuals with elevated PSA levels. Patients with low-risk or favorable intermediate-risk prostate cancer may choose active surveillance over immediate curative treatment. Surgery and radiation therapy have good outcomes but can lead to complications.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer

Idris Olasunmbo Ola, Kirsi Talala, Teuvo Tammela, Kimmo Taari, Teemu Murtola, Paula Kujala, Jani Raitanen, Anssi Auvinen

Summary: PSA-based screening can reduce prostate cancer mortality, but may also lead to overdetection of low-risk disease. The incidence of prostate cancer is associated with PSA levels, with higher PSA values indicating an increased risk of aggressive disease. Risk stratification and appropriate rescreening intervals can help reduce overdetection.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality

Danielle S. Bitterman, Ming-Hui Chen, Jing Wu, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff, Eric J. Small, Anthony V. D'Amico

Summary: This study found that low testosterone level at PSA failure in high-risk patients with PC treated with RT is associated with increased PCSM and ACM risk, and that higher PSAn is also associated with worse PCSM and ACM risk, especially in men with normal testosterone levels at PSA failure.

CANCER (2021)

添加到收藏夹

Article Urology & Nephrology

Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer

Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol

Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.

EUROPEAN UROLOGY (2023)

添加到收藏夹

Article Oncology

Association Between Prostate-Specific Antigen Screening and Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White US Veterans

Michael V. Sherer, Edmund M. Qiao, Nikhil V. Kotha, Alexander S. Qian, Brent S. Rose

Summary: PSA screening is associated with reduced risk of prostate cancer-specific mortality among both non-Hispanic Black men and non-Hispanic White men. Annual screening is particularly important for reducing the risk of prostate cancer-specific mortality among Black men.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States

David-Dan Nguyen, Quoc-Dien Trinh, Alexander P. Cole, Kerry L. Kilbridge, Brandon A. Mahal, Matt Hayn, Moritz Hansen, Paul K. J. Han, Jesse D. Sammon

Summary: This study examined the impact of patient health literacy (HL) on prostate-specific antigen (PSA) screening rates and shared decision making (SDM). Findings showed that men with higher HL had higher rates of PSA screening, but when SDM was present, those with higher HL were less likely to undergo PSA screening.

CANCER (2021)

添加到收藏夹

Article Primary Health Care

Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017

Ashley Kieran Clift, Carol A. C. Coupland, Julia Hippisley-Cox

Summary: The study evaluated the rates of PSA testing and opportunistic screening in England between 1998 and 2017, finding a substantial number of men opt in to opportunistic prostate cancer screening despite uncertainties, and estimated the contamination rate in the CAP trial.

BRITISH JOURNAL OF GENERAL PRACTICE (2021)

添加到收藏夹

Article Urology & Nephrology

A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer

Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol

Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.

EUROPEAN UROLOGY (2023)

添加到收藏夹

Review Urology & Nephrology

Prostate-Specific Antigen Screening in Transgender Patients

Farnoosh Nik-Ahd, Andrew Jarjour, Jane Figueiredo, Jennifer T. Anger, Maurice Garcia, Peter R. Carroll, Matthew R. Cooperberg, Adriana C. Vidal, Stephen J. Freedland

Summary: The global population of transgender individuals is approximately 0.4-1.3%, and transgender women retain their prostates even after gender-affirmation surgery, requiring ongoing screening for prostate cancer. However, there is limited knowledge about prostate-specific antigen (PSA) screening in this population.

EUROPEAN UROLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer

Youngjun Boo, Jae Hoon Chung, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Wan Song

Summary: As the incidence of prostate cancer has increased, there is controversy surrounding the use of prostate-specific antigen (PSA) for screening due to its low specificity. In this study, we compared the diagnostic performance of prostate health index (PHI) density (PHID) with PSA, PSA density (PSAD), and PHI as a triaging test for the detection of prostate cancer and clinically significant prostate cancer (csPCa). The results showed that PHID had the highest area under the curve (AUC) for both prostate cancer and csPCa detection, followed by PHI, PSAD, and PSA. Using PHID as a triaging test could significantly reduce unnecessary biopsies for prostate cancer. The findings suggest that PHID can be utilized in a clinical setting to assess the risk of prostate cancer and csPCa.

BIOMEDICINES (2023)

添加到收藏夹

Editorial Material Urology & Nephrology

Prostate cancer screening: a new way forward or another false start?

Peter C. Albertsen

Summary: PSA testing can identify men with significant prostate cancer, but may also lead to overdiagnosis of indolent tumors. Using germline single-nucleotide polymorphisms to identify men at genetic risk of developing prostate cancer could be a promising approach, but changing the current screening paradigm poses challenges based on preliminary findings.

NATURE REVIEWS UROLOGY (2021)

添加到收藏夹

Article Oncology

Screening for prostate cancer in a city in Japan: age-specific prostate-specific antigen cutoff thresholds

Hideyuki Terao, Hirotaka Nagasaka, Shotaro Yamamoto, Atsuto Suzuki, Kimitsugu Usui, Noboru Nakaigawa, Takeshi Kishida, Kaname Watanabe, Sho Nakamura, Hiroto Narimatsu

Summary: The cutoff values for older men in prostate cancer screening may need to be reexamined, as the current Japanese guidelines recommend a cutoff of 4.0 ng/mL regardless of age. By analyzing data from a prostate screening cohort in Japan, this study suggests that using a higher cutoff value for men over 80 years old may help reduce unnecessary biopsies and costs.

CANCER CAUSES & CONTROL (2023)

添加到收藏夹

Article Urology & Nephrology

Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity

Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, Jeff Michalski, Robert L. Grubb, Seth A. Strope, Jennifer Haslag-Minoff, Jay F. Piccirillo, Jay P. Ciezki, Eric A. Klein, Chandana A. Reddy, Changhong Yu, Michael W. Kattan, Adam S. Kibel

EUROPEAN UROLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer

Bruce L. Jacobs, Yun Zhang, Florian R. Schroeck, Ted A. Skolarus, John T. Wei, James E. Montie, Scott M. Gilbert, Seth A. Strope, Rodney L. Dunn, David C. Miller, Brent K. Hollenbeck

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Oncology

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D'Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, Dorothy A. Shead

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)

添加到收藏夹

Article Oncology

Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D'Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, Maria Ho

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)

添加到收藏夹

Article Oncology

Prostate Cancer, Version 2.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D'Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, Maria Ho

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)

添加到收藏夹

Article Urology & Nephrology

Surgeon Variation in Patient Quality of Life After Radical Prostatectomy

Arthur Hartz, Tao He, Seth Strope, D. Richard Cutler, Gerald Andriole, Christopher Dechet

JOURNAL OF UROLOGY (2013)

添加到收藏夹

Editorial Material Urology & Nephrology

Downstream Complications Following Urinary Diversion EDITORIAL COMMENT

Seth A. Strope

JOURNAL OF UROLOGY (2013)

添加到收藏夹

Article Urology & Nephrology

Survival Impact of Followup Care after Radical Cystectomy for Bladder Cancer

Seth A. Strope, Su-Hsin Chang, Ling Chen, Gurdarshan Sandhu, Jay F. Piccirillo, Mario Schootman

JOURNAL OF UROLOGY (2013)

添加到收藏夹

Article Urology & Nephrology

Defining the Potential of Neoadjuvant Chemotherapy Use as a Quality Indicator for Bladder Cancer Care

Goutham Vemana, Kenneth G. Nepple, Joel Vetter, Gurdarshan Sandhu, Seth A. Strope

JOURNAL OF UROLOGY (2014)

添加到收藏夹

Article Health Care Sciences & Services

The Impact of Technology Diffusion on Treatment for Prostate Cancer

Florian R. Schroeck, Samuel R. Kaufman, Bruce L. Jacobs, Yun Zhang, Alon Z. Weizer, Jeffrey S. Montgomery, Scott M. Gilbert, Seth A. Strope, Brent K. Hollenbeck

MEDICAL CARE (2013)

添加到收藏夹

Article Oncology

Early oncologic outcomes of robotic vs. open radical cystectomy for urothelial cancer

Kenneth G. Nepple, Seth A. Strope, Robert L. Grubb, Adam S. Kibel

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)

添加到收藏夹

Editorial Material Urology & Nephrology

Never Events: Centers for Medicare and Medicaid Services Complications After Radical Cystectomy EDITORIAL COMMENT

Seth A. Strope

UROLOGY (2013)

添加到收藏夹

Article Urology & Nephrology

A Population-based Analysis of Contemporary Rates of Reoperation for Penile Prosthesis Procedures

Shaun Grewal, Joel Vetter, Steven B. Brandes, Seth A. Strope

UROLOGY (2014)

添加到收藏夹

Article Urology & Nephrology

Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT

Vivek Verma, Ling Chen, Jeff M. Michalski, Yanle Hu, Wenjun Zhang, Kathryn Robinson, Shivam Verma, Laura Eschen, Sandra Fergus, Dan Mullen, Seth Strope, Robert Grubb, Hiram A. Gay

WORLD JOURNAL OF UROLOGY (2015)

添加到收藏夹

Article Otorhinolaryngology

Exploring SEER-Medicare for Changes in the Treatment of Laryngeal Cancer among Elderly Medicare Beneficiaries

Raymond A. Jean, Dorina Kallogjeri, Seth A. Strope, Frances Mei Hardin, Jason T. Rich, Jay F. Piccirillo

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2014)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.